DOCSLIB.ORG

Specialist Laboratory Services Information Manual Spec Labo Serv Info

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Specialist Laboratory Services Information Manual Spec Labo Serv Info SPECIALIST SPECIALIST LABORATORY LABORATORY SERVICES SERVICES INFORMATION INFORMATION MANUAL MANUAL 18th EDITION, MARCH 2016 18th EDITION, MARCH 2016 Specialists in Endocrinology. Experts in Immunoassay. Specialists in Endocrinology. Experts in Immunoassay. Table of Contents Table of Contents Page Page TABLE OF CONTENTS 1 TABLE OF CONTENTS 1 NATIONWIDE SPECIALIST LABORATORY 5 NATIONWIDE SPECIALIST LABORATORY 5 The Laboratory 5 The Laboratory 5 Methodology 5 Methodology 5 Quality Assurance 5 Quality Assurance 5 Personnel 6 Personnel 6 Research and Clinical Trial Assays 6 Research and Clinical Trial Assays 6 Using our Services 6 Using our Services 6 Request Forms 6 Request Forms 6 Sample Collection Procedures 6 Sample Collection Procedures 6 Sample Dispatch 6 Sample Dispatch 6 Sample Results 6 Sample Results 6 Turnaround Time 7 Turnaround Time 7 SI units 7 SI units 7 Reference Ranges 7 Reference Ranges 7 Web Site 7 Web Site 7 ClinPath Club Meetings – free CPD 7 ClinPath Club Meetings – free CPD 7 Specialist Clinical and Laboratory Endocrinology Advisors 8 Specialist Clinical and Laboratory Endocrinology Advisors 8 About this manual 9 About this manual 9 THYROID FUNCTION 10 THYROID FUNCTION 10 Canine Hypothyroidism 10 Canine Hypothyroidism 10 Individual tests 11 Individual tests 11 Thyroid Panels and Dynamic Tests 12 Thyroid Panels and Dynamic Tests 12 Greyhound Thyroid Panels 13 Greyhound Thyroid Panels 13 Monitoring Therapy 14 Monitoring Therapy 14 Diagnosing Canine Hypothyroidism Flowchart 15 Diagnosing Canine Hypothyroidism Flowchart 15 Feline Hyperthyroidism (Thyrotoxicosis) 16 Feline Hyperthyroidism (Thyrotoxicosis) 16 Individual Tests 16 Individual Tests 16 Thyroid Panels and Dynamic Tests 16 Thyroid Panels and Dynamic Tests 16 Feline Hypothyroidism 18 Feline Hypothyroidism 18 Equine Hypothyroidism 19 Equine Hypothyroidism 19 ADRENOCORTICAL FUNCTION 20 ADRENOCORTICAL FUNCTION 20 Canine Hyperadrenocorticism (HAC - Cushing’s Disease) 20 Canine Hyperadrenocorticism (HAC - Cushing’s Disease) 20 Laboratory Services Manual 18th edition, March 2016 Page 1 Laboratory Services Manual 18th edition, March 2016 Page 1 NationWide Specialist Laboratory NationWide Specialist Laboratory Individual tests 20 Individual tests 20 Dynamic test protocols 20 Dynamic test protocols 20 Monitoring Therapy 25 Monitoring Therapy 25 Monitoring Therapy Using “Pre-Pill” Single Cortisol Samples 25 Monitoring Therapy Using “Pre-Pill” Single Cortisol Samples 25 Interpretation of Cortisol Measured before and After Trilostane 26 Interpretation of Cortisol Measured before and After Trilostane 26 Diagnosing Canine Hyperadrenocorticism Flowchart 27 Diagnosing Canine Hyperadrenocorticism Flowchart 27 Canine Hypoadrenocorticism - Addison’s Disease 28 Canine Hypoadrenocorticism - Addison’s Disease 28 Diagnosis 28 Diagnosis 28 Monitoring therapy 29 Monitoring therapy 29 Feline Hyperadrenocorticism (HAC - Cushing’s Disease) 30 Feline Hyperadrenocorticism (HAC - Cushing’s Disease) 30 Guinea Pig Hyperadrenocorticism (HAC - Cushing’s Disease) 32 Guinea Pig Hyperadrenocorticism (HAC - Cushing’s Disease) 32 Equine Pituitary Pars Intermedia Dysfunction (PPID) 33 Equine Pituitary Pars Intermedia Dysfunction (PPID) 33 Equine Metabolic Syndrome (EMS) 35 Equine Metabolic Syndrome (EMS) 35 Adrenal Disease In Ferrets 36 Adrenal Disease In Ferrets 36 Adrenal Sex Hormone Imbalance In Dogs (SHAP) 36 Adrenal Sex Hormone Imbalance In Dogs (SHAP) 36 Canine Full Adrenal Sex Hormone Profile 37 Canine Full Adrenal Sex Hormone Profile 37 Aldosterone 38 Aldosterone 38 MALE REPRODUCTIVE FUNCTION 40 MALE REPRODUCTIVE FUNCTION 40 Cryptorchid/Testicular Function 40 Cryptorchid/Testicular Function 40 FEMALE REPRODUCTIVE FUNCTION 42 FEMALE REPRODUCTIVE FUNCTION 42 Ovulation Detection 42 Ovulation Detection 42 Ovarian Tissue Detection 43 Ovarian Tissue Detection 43 Equine Inhibin 45 Equine Inhibin 45 Equine AMH 45 Equine AMH 45 PREGNANCY TESTS 46 PREGNANCY TESTS 46 Equine Progesterone (Early Indicative Pregnancy Test) 46 Equine Progesterone (Early Indicative Pregnancy Test) 46 Equine Pregnant Mare Serum Gonadotrophin (PMSG) 46 Equine Pregnant Mare Serum Gonadotrophin (PMSG) 46 Equine Oestrone Sulphate Pregnancy Test 46 Equine Oestrone Sulphate Pregnancy Test 46 Total Urinary Oestrogens (TUE) 46 Total Urinary Oestrogens (TUE) 46 Summary Table of Equine Pregnancy Tests 47 Summary Table of Equine Pregnancy Tests 47 Canine Pregnancy Test - Relaxin 47 Canine Pregnancy Test - Relaxin 47 Feline Pregnancy Test - Relaxin 47 Feline Pregnancy Test - Relaxin 47 Faecal Pregnancy Detection 47 Faecal Pregnancy Detection 47 Laboratory Services Manual 18th edition, March 2016 Page 2 Laboratory Services Manual 18th edition, March 2016 Page 2 NationWide Specialist Laboratory NationWide Specialist Laboratory GASTROINTESTINAL AND PANCREATIC 48 GASTROINTESTINAL AND PANCREATIC 48 Trypsin-Like Immunoreactivity (TLI) 48 Trypsin-Like Immunoreactivity (TLI) 48 Lipase iPLA 48 Lipase iPLA 48 Vitamin B12/Folate 49 Vitamin B12/Folate 49 Pancreatic Lipase Immunoreactivity (PLI) 49 Pancreatic Lipase Immunoreactivity (PLI) 49 Insulin 50 Insulin 50 Fructosamine 51 Fructosamine 51 CALCIUM DISORDERS 52 CALCIUM DISORDERS 52 Parathyroid Hormone (PTH) and Ionised Calcium (iCa) 52 Parathyroid Hormone (PTH) and Ionised Calcium (iCa) 52 Parathyroid Hormone Related Peptide (PTHrP) 54 Parathyroid Hormone Related Peptide (PTHrP) 54 Vitamin D Metabolites 55 Vitamin D Metabolites 55 OTHER ENDOCRINE 56 OTHER ENDOCRINE 56 Insulin-Like Growth Factor 1 (IGF-1) 56 Insulin-Like Growth Factor 1 (IGF-1) 56 Erythropoietin (EPO) 56 Erythropoietin (EPO) 56 Gastrin (Special Request Assay) 56 Gastrin (Special Request Assay) 56 Renin (Special Request Assay) 57 Renin (Special Request Assay) 57 Glucagon (Special Request Assay) 58 Glucagon (Special Request Assay) 58 Please note at the current time we are unable to perform Glucagon analysis due to Please note at the current time we are unable to perform Glucagon analysis due to the withdrawal of the method we had validated. 58 the withdrawal of the method we had validated. 58 We will be looking at other methods for the future. 58 We will be looking at other methods for the future. 58 NT-proBNP – Canine/Feline Cardiac Marker 59 NT-proBNP – Canine/Feline Cardiac Marker 59 Canine Benign Prostate Hyperplasia (BPH) 60 Canine Benign Prostate Hyperplasia (BPH) 60 THERAPEUTIC DRUG MONITORING 61 THERAPEUTIC DRUG MONITORING 61 Phenobarbitone 61 Phenobarbitone 61 Potassium Bromide 61 Potassium Bromide 61 Levetiracetam (Keppra®) 61 Levetiracetam (Keppra®) 61 Digoxin 62 Digoxin 62 Cyclosporine 62 Cyclosporine 62 Laboratory Services Manual 18th edition, March 2016 Page 3 Laboratory Services Manual 18th edition, March 2016 Page 3 NationWide Specialist Laboratory NationWide Specialist Laboratory ENDOCRINE THERAPEUTIC MONITORING 63 ENDOCRINE THERAPEUTIC MONITORING 63 Basic Vetoryl Monitor 63 Basic Vetoryl Monitor 63 Vetoryl Monitor Plus 63 Vetoryl Monitor Plus 63 Vetoryl - treatment and monitoring of canine hac 65 Vetoryl - treatment and monitoring of canine hac 65 Basic Thyforon 66 Basic Thyforon 66 Thyforon Monitor Plus 66 Thyforon Monitor Plus 66 Basic Felimazole 66 Basic Felimazole 66 Felimazole Monitor Plus 67 Felimazole Monitor Plus 67 Felimazole - diagnosis of feline hyperthyroidism 68 Felimazole - diagnosis of feline hyperthyroidism 68 Felimazole - treatment and monitoring of feline hyperthyroidism 69 Felimazole - treatment and monitoring of feline hyperthyroidism 69 SEROLOGY/IMMUNOLOGY 70 SEROLOGY/IMMUNOLOGY 70 Acetylcholine Receptor Antibodies (ACRAB) 70 Acetylcholine Receptor Antibodies (ACRAB) 70 Type 2M Muscle Fibre Antibody (2MAB) 70 Type 2M Muscle Fibre Antibody (2MAB) 70 Sarcoptic Mange Antibody (SMA) 70 Sarcoptic Mange Antibody (SMA) 70 Allergy Testing 71 Allergy Testing 71 ONCOLOGY 72 ONCOLOGY 72 Thymidine kinase 72 Thymidine kinase 72 REFERENCES 73 REFERENCES 73 APPENDICES 74 APPENDICES 74 I. Conversion Factors 74 I. Conversion Factors 74 II. Assay Sample Requirements 75 II. Assay Sample Requirements 75 III. Specialist Biochemistry Profiles 76 III. Specialist Biochemistry Profiles 76 IV. Laboratory Request Form 77 IV. Laboratory Request Form 77 V. Laboratory Assay Schedule 78 V. Laboratory Assay Schedule 78 VI. Laboratory Pre-Paid Label 79 VI. Laboratory Pre-Paid Label 79 Laboratory Services Manual 18th edition, March 2016 Page 4 Laboratory Services Manual 18th edition, March 2016 Page 4 NATIONWIDE SPECIALIST LABORATORY NATIONWIDE SPECIALIST LABORATORY NationWide Specialist Laboratory (formerly Dechra Specialist Laboratories, originally NationWide Specialist Laboratory (formerly Dechra Specialist Laboratories, originally Cambridge Specialist Laboratory Services) was formed in 1998 by a small group of Cambridge Specialist Laboratory Services) was formed in 1998 by a small group of scientists and technicians with many years of experience in veterinary diagnostics and scientists and technicians with many years of experience in veterinary diagnostics and radioimmunoassay. They saw a demand for the provision of a unique level of analytical radioimmunoassay. They saw a demand for the provision of a unique level of analytical quality in the field of veterinary endocrinology. The aim of the laboratory is to find the quality in the field of veterinary endocrinology. The aim of the laboratory is to find the best or “gold standard” assay technologies for hormone analysis that can be made best or “gold standard” assay technologies for hormone analysis that can be made available to the veterinary profession at reasonable
Load more

Recommended publications
  • Hyperthyroidism with an FSH- and TSH-Secreting Pituitary Adenoma
    • Hyperthyroidism with an FSH- and TSH-secreting pituitary adenoma JOHN BERMINGHAM, DO LOUIS C. HAENEL, DO A 34-year-old man was found noma is rare. The combined secretion of follicle- to have elevated thyroxine (T 4 ), triiodothy- stimulating hormone (FSH) and TSH by a pi- ronine (T3 ), calculated free T4 , thyroid- tuitary adenoma is rarer. But with current stimulating hormone (TSH), follicle-stimu- widespread use of TSH assays, plus the future lating hormone (FSH), and alpha subunits clinical availability of more sensitive TSH as- of TSH and FSH. A computed tomography says as well as TSH bioactivity testing, more scan of the head showed a 16-mm mac- patients will have pituitary-induced hyperthy- roadenoma of the pituitary gland. There roidism correctly diagnosed, and the disorder was no evidence of loss or excess secre- will be better understood. tion of other pituitary hormones. The large As illustrated in the following case study, chromophobe adenoma was removed via making the correct diagnosis of primary ver- a transphenoidal approach. The patient sus secondary hyperthyroidism is imperative has been taken off all medication. Thyroid because the treatment and potential conse- function has returned to normal and there quences of each of these diseases are totally has been no loss of pituitary secretory ca- different. pacity of other pituitary hormones. The oc- currence of a combined TSH- and FSH- Report of case secreting pituitary adenoma is rare; to the In August 1985, a 34-year-old man was seen with authors knowledge, only one case has complaints that were initially vague and nonspe- been documented in the literature.
    [Show full text]
  • Ischemia-Modified Albumin Level in Type 2 Diabetes Mellitus
    Disease Markers 24 (2008) 311–317 311 IOS Press Ischemia-modified albumin level in type 2 diabetes mellitus – Preliminary report Agnieszka Piwowara,∗, Maria Knapik-Kordeckab and Maria Warwasa aDepartment of Pharmaceutical Biochemistry of Wroclaw Medical University, Wrocław, Poland bDepartment and Clinic of Angiology, Hypertension and Diabetology of Wroclaw Medical University, Wrocław, Poland Abstract. Aim: The main goal of the present study was the evaluation of ischemia-modified albumin (IMA) in patients with type 2 diabetes mellitus and estimation of its connection with vascular complications, glycemic control, hypertension, dyslipidemia and obesity. Methods: In 76 diabetic patients and 25 control subjects, a plasma level of IMA by manually performed, spectrophotometric Co(II)-albumin binding assay was determined. Other parameters such as glucose, fructosamine, HbA1c, total cholesterol and its fractions (HDL, LDL), triglicerydes were estimated by routine methods. Results: Diabetic patients had significantly higher level of IMA in comparison with control subjects. There were not significant differences between groups with various states of vascular complications although the lowest concentration of IMA was observed in patients with microangiopathy. Patients with poor glycemic control had higher IMA level in comparison with these with good glycemic control. Significant correlation was observed between IMA and HbA1c. Among the risk factors, only blood pressure and LDL showed a weak relationship with IMA level. Conclusions: Our results revealed, for the first time, higher level of IMA in diabetic patients which confirms that it may be of non-cardiac origin. We can suggest that the albumin molecule in plasma of diabetic patients is modified in the chronic hypoxia conditions provoked mainly by hyperglycemia and oxidative stress in diabetes.
    [Show full text]
  • A Case of Cushing Syndrome with Both Secondary Hypothyroidism and Hypercalcemia Due to Postoperative Adrenal Insufficiency
    Endocrine Journal 2004, 51 (1), 105–113 NOTE A Case of Cushing Syndrome with Both Secondary Hypothyroidism and Hypercalcemia Due to Postoperative Adrenal Insufficiency MASAHITO KATAHIRA, TSUTOMU YAMADA* AND MASAHIKO KAWAI* Department of Internal Medicine, Kyoritsu General Hospital, Nagoya 456-8611, Japan *Division of Endocrinology, Department of Internal Medicine, Okazaki City Hospital, Okazaki 444-8553, Japan Abstract. A 48-year-old woman was referred to our hospital because of secondary hypothyroidism. Upon admission a left adrenal tumor was also detected using computed tomography. Laboratory data and adrenal scintigraphy were compatible with Cushing syndrome due to the left adrenocortical adenoma, although she showed no response to the TRH stimulation test. Hypercortisolism resulting in secondary hypothyroidism was diagnosed. After a left adrenalectomy, hydrocortisone administration was begun and the dose was reduced gradually. After discharge on the 23rd postoperative day, she began to suffer from anorexia. ACTH level remained low, and serum cortisol, free thyroxine and TSH levels were within the normal range. Since her condition became worse, she was re-admitted on the 107th postoperative day at which time serum calcium level was high (15.6 mg/dl). Both ACTH response to the CRH stimulation test and TSH response to the TRH stimulation test were restored to almost normal levels, but there was no response of cortisol to CRH stimulation test. We diagnosed that the hypercalcemia was due to adrenal insufficiency. Although the serum calcium level decreased to normal after hydrocortisone was increased (35 mg/day), secondary hypothyroidism recurred. It was suggested that sufficient glucocorticoids suppressed TSH secretion mainly at the pituitary level, which resulted in secondary (corticogenic) hypothyroidism.
    [Show full text]
  • The Evaluation of Cardiac Markers in Myocardial Infarction Patients
    Volume : 4 | Issue : 5 | May 2015 ISSN - 2250-1991 Research Paper Medical Science The Evaluation Of Cardiac Markers In Myocardial Infarction Patients Department of Medical Laboratory Science, College of Applied Ramprasad N Medical Sciences, Shaqra University, Al- Quwayiyah, Kingdom of Saudi Arabia, Corresponding Author Department of Medical Laboratory Science, College of Applied Samir Abdulkarim Medical Sciences, Shaqra University, Al- Quwayiyah, Kingdom of Alharbi Saudi Arabia Abdullah Habbab Laboratory Director, Diagnostic Laboratory, Al- Quwayiyah Gener- Alharbi al Hospital, Kingdom of Saudi Arabia. Background: Sudden cardiac death due to acute myocardial infarction (MI) is the most prevalent cause of death in young and adults. MI is a life threatening condition that needs emergency diagnosis and early treatment in the emergency room. Some researchers look for various clinical markers, which would help early diagnosis of the disease. Aim: In the present study, our aim was to investigate the lipid profile and cardiac enzymes in MI patients in Al- Quwayiyah region of Saudi Arabia. Materials and methods: This study included total 38 patients with MI and 46 age and sex matched healthy controls. Various lipid profile parameters and cardiac enzymes like Creatinine phosphokinase (CPK), Creatinine kinase- MB (CK- MB), lactate dehydrogenase (LDH), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) levels were measured ABSTRACT and compared. This study was conducted in Al- Quwayiyah General Hospital, Saudi Arabia. Results: The significantly increased levels of cardiac enzymes (P<0.001) in MI patients when compared to control groups. Conclusion: The present study illustrated that assessing of lipid profiles and serum cardiac enzymes are the markedly very useful as it may serve as a useful monitor to judge the prognosis of the MI patients.
    [Show full text]
  • A Comparative Study of Creatine Kinase-MB and Troponin Levels Among Diabetic and Non Diabetic Patients with Acute MI
    ORIGINAL ARTICLE A comparative study of Creatine Kinase-MB and Troponin levels among diabetic and non diabetic patients with Acute MI AWAIS ANWAR1, HASAN AKBAR KHAN2, SAMRA HAFEEZ3, KANWAL FIRDOUS4 ABSTRACT In diabetic patients myocardial infarction (MI) is a major cause of death. Weak metabolic control is very common in diabetic patients with MI and if blood glucose levels are not controlled with different treatments may produce medical complications. Hyperglycemia, CK-MB and tropanin levels are very important biomarkers for the assessment of MI. The blood glucose (325.56±23.6), CK-MB (350.6±95.23) and Tropanin (6.16±2.23) levels in diabetics individuals showed P<0.001 significant results. Key words: Myocardial infarction (MI),Creatine kinase (CK),Tropanin. INTRODUCTION produced in pregnant ladies without any diabetic history due to the stress (Kosaka et al., 2005). Commonly myocardial infarction (MI) or acute Creatine kinase (CK) is an intracellular enzyme myocardial infarction (AMI) is called heart attack and found its high quantity in skeletal muscles, it occurs by the blockages of blood supply to a part of myocardium, and brain; smaller amounts also occur the heart (Agarwall,. 2009). When supply of blood in other visceral tissues. A CK-MB test is used as stops to the heart it causes damaging of the heart biological parameter in MI (Zeller et al., 2005). In the muscle. There are many symptom of MI but the most case of MI its concentration in the blood increases common is chest pain or which may travel into the than the normal levels. Different researchers found shoulder, arm, back, neck, or jaw that creatine kinase levels increases due to heart (Aghaeishahsavari,.
    [Show full text]
  • Clinical Research Protocol
    CLINICAL RESEARCH PROTOCOL NCT02399475 The Thyroid Axis in Older Individuals with Persistent Subclinical Hypothyroidism: a Mechanistic, Randomized, Double-Blind, Cross-Over Study of Levothyroxine and Liothyronine Administration Regulatory Sponsor: Anne R. Cappola, MD, ScM Division of Endocrinology, Diabetes, and Metabolism 12-136 Translational Research Center 3400 Civic Center Blvd, Bldg 421 Philadelphia, PA 19104-5160 (215) 573 5359 Funding Sponsor: National Institute on Aging, NIH Medications Used: Thyrotropin Releasing Hormone (TRH) Levothyroxine (LT4) Liothyronine (LT3) Protocol Number: 821564 IND Number: 125167 Initial version:[11/26/2014] Amended [7/22/2015] Amended: [12/18/2014] Amended [9/9/2015] Amended: [1/2/2015] Amended [8/25/2016] Amended: [3/26/2015] Amended [12/23/2016] Amended: [5/13/2015] Amended [3/24/2017] Amended: [06/04/2015] Amended [9/26/2017] Amended: [6/10/2015] Amended [12/18/2017] (additional next page) Amended [12/18/18] CONFIDENTIAL This material is the property of the University of Pennsylvania. Do not disclose or use except as authorized in writing by the study sponsor LT4 and LT3 in Subclinical Hypothyroidism Page ii Version 12/18/2018 Table of Contents STUDY SUMMARY ......................................................................................................... 1 1 INTRODUCTION ...................................................................................................... 3 1.1 BACKGROUND ....................................................................................................
    [Show full text]
  • The MAS Omni QC Family
    Thermo Scientific MAS Omni Quality Control Products Results you can trust The MAS Omni QC family Eliminate up to four routinely run vials Streamline your workflow Reduce your costs Streamline your workflow Consolidate multiple QC products Cardiac Panel QC STAT QC consolidated into: Omni•CARDIO Routine Immunoassay QC Tumor Marker QC Specialty Immunoassay QC General Chemistry QC consolidated into: Serum Protein / Immunology QC Omni•IMMUNE or consolidated into: Omni•IMMUNE PRO Omni•CORE MAS Omni•CARDIO™ Thermo Scientific™ MAS® Omni•CARDIO consolidates a comprehensive cardiac marker panel with the new generation of STAT analytes including D-Dimer, hCG, Myeloperoxidase and Procalcitonin. Value assignment is provided for key instrument systems including Abbott Architect, Beckman Coulter Access, AU and UniCel systems, Ortho Clinical Diagnostics VITROS, Roche Cobas and Elecsys systems and Siemens Advia, Dimension, Dimension Vista, Immulite and Stratus systems. Part Number Level Bottles & Size Storage & Stability Matrix OCRD-UL Ultra Low OCRD-L Low 36 months @ -25 to -15 ºC OCRD-101 1 15 days @ 2-8 ºC (for BNP-32, CK-MB, D-Dimer, OCRD-202 2 6 x 3 mL Assayed Digitoxin, hCG, hsCRP, Myeloperoxidase, Human Serum OCRD-303 3 Procalcitonin, Total CK, Troponin-I and Troponin-T) 10 days @ 2-8 ºC (for Myoglobin and NT-proBNP) Tri-Level Multi-Pack OCRD-MP (2 vials each level 1/2/3) Analytes Brain Natriuretic Peptide-32 (BNP-32) Beta Human Chorionic Gonadotropin (b-hCG) Procalcitonin (PCT) Creatinine Kinase-MB (CK-MB) High Sensitivity C-Reactive Protein (hsCRP)
    [Show full text]
  • Kaplan & Sadock's Study Guide and Self Examination Review In
    Kaplan & Sadock’s Study Guide and Self Examination Review in Psychiatry 8th Edition ← ↑ → © 2007 Lippincott Williams & Wilkins Philadelphia 530 Walnut Street, Philadelphia, PA 19106 USA, LWW.com 978-0-7817-8043-8 © 2007 by LIPPINCOTT WILLIAMS & WILKINS, a WOLTERS KLUWER BUSINESS 530 Walnut Street, Philadelphia, PA 19106 USA, LWW.com “Kaplan Sadock Psychiatry” with the pyramid logo is a trademark of Lippincott Williams & Wilkins. All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright. Printed in the USA Library of Congress Cataloging-in-Publication Data Sadock, Benjamin J., 1933– Kaplan & Sadock’s study guide and self-examination review in psychiatry / Benjamin James Sadock, Virginia Alcott Sadock. —8th ed. p. cm. Includes bibliographical references and index. ISBN 978-0-7817-8043-8 (alk. paper) 1. Psychiatry—Examinations—Study guides. 2. Psychiatry—Examinations, questions, etc. I. Sadock, Virginia A. II. Title. III. Title: Kaplan and Sadock’s study guide and self-examination review in psychiatry. IV. Title: Study guide and self-examination review in psychiatry. RC454.K36 2007 616.890076—dc22 2007010764 Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication.
    [Show full text]
  • Lifesign MI 3-In-1 Package Insert.Pdf
    MIMyoglobin/CK-MB/Troponin I 3 IN 1 Point-of-care cardiac tests for the simultaneous qualitative detection of Myoglobin, CK-MB and Troponin I in blood, plasma and serum for the rapid diagnosis of myocardial infarction Manufactured by MF Manufactured for: EC REP Princeton BioMeditech Corp. MT Promedt Consulting GmbH 4242 U.S. Hwy 1 A PBM Group Company Altenhofstrasse 80 Monmouth Junction, NJ 08852 66386 St. Ingbert 85 Orchard Road Germany Skillman,NJ 08558 +49-68 94-58 10 20 800-526-2125, 732-246-3366 596 -4/24/12 www.lifesignmed.com P-56331-B LifeSign MI® Myoglobin/CK-MB/Troponin I Rapid Test For in vitro Diagnostic Use Only A Simple and Rapid One-Step Immunoassay for the Simultaneous Qualitative Detection of Myoglobin, CK-MB, and Cardiac Troponin I in Human Whole Blood, Serum, or Plasma. Intended Use: For the simultaneous qualitative determination of myoglobin, CK-MB, and troponin I in human whole blood, plasma or serum as an aid in the diagnosis of acute myocardial infarction in emergency room, critical care, point-of-care, and hospital settings. The LifeSign MI® Myoglobin/CK-MB/Troponin I Test provides a qualitative analytical test result. The qualitative nature of this assay does not provide infor- mation about change - either the rise or fall - in the concentration of myoglobin, CK-MB, and cardiac troponin I with single testing. A quantitative method should be used, if desired, to quantitate the concentration of myoglobin, CK-MB, and cardiac troponin I at any given time. Only with serial testing could a temporal change in the level of myoglobin, CK-MB, and cardiac troponin I be concluded.
    [Show full text]
  • 3 in 1 Troponin/Myoglobin/CK-MB
    Cortez DIAGNOSTICS, INC. 21250 Califa St. Suite 102 and 116, Woodland Hills, CA 91367 USA Tel: (818) 591-3030 Fax: (818) 591-8383 E-mail: [email protected] Web site: www.rapidtest.com See external label 2°C-30°C =25 or 50 tests Cat. #166779-1-37 One Step Troponin I/ CKMB/ Myoglobin RapiCard™ InstaTest Cat # 166779-1-37 One-step immuno-chromatographic assay for the detection of cTnI, CK-MB, and Myoglobin in human whole blood, serum and plasma For in vitro Diagnostic Use INTENDED USE The Cortez AMI 3 IN 1 Test is a rapid immunoassay for the determination of Cardiac Troponin I (cTnI), Creatine Kinase MB (CK-MB), and Myoglobin in human whole blood, serum and plasma specimens at cutoff concentrations of 0.5ng/ml, 5.0ng/ml, and 80ng/ml respectively, as an aid in the diagnosis of Acute Myocardial Infarction (AMI). Test results should be interpreted by the physician along with other test results and patient clinical symptoms. SUMMARY AND EXPLANATION When the myocardial infarction (MI) occurs in the hypoperfused region of the myocardium, oxygen can no longer be supplied to the cells in the region. Cell death is inevitable if oxygen is not restored within 10-15 min. Cell death results in the release of certain proteins from within cytoplasm into the blood stream. Some proteins are exclusive to and predominant in the cardiac muscle cells; they can function as cardiac makers and be detected in the blood specimens of AMI patients by specialized immunoassays.1-3 Unfortunately none of cardiac markers that have been discovered show early release, have 100% cardiac specificity, and a substantial life time in circulation.
    [Show full text]
  • Society for Endocrinology National Clinical Cases 2021
    Endocrine Abstracts June 2021 Volume 74 ISSN 1479-6848 (online) Society for Endocrinology National Clinical Cases 2021 22 June 2021, Online published by Online version available at bioscientifica www.endocrine-abstracts.org Volume 74 Endocrine Abstracts June 2021 Society for Endocrinology National Clinical Cases 2021 Tuesday 22 June 2021 Online Meeting Chairs Dr Anna Crown (Brighton) Dr Miles Levy (Leicester) Dr Annice Mukherjee (Manchester) Dr Michael O’Reilly (Dublin) Abstract Marking Panel Dr Kristien Boelart (Birmingham) Dr Karin Bradley (Bristol) Dr Simon Howell (Preston) Dr Andrew Lansdown (Cardiff) Dr Miles Levy (Leicester) Dr Daniel Morganstein (London) Dr Michael O’Reilly (Dublin) Professor Robert Semple (Edinburgh) Dr Peter Taylor (Cardiff) Dr Helen Turner (Oxford) Professor Bijay Vaidya (Exeter) Dr Nicola Zammitt (Edinburgh) Society for Endocrinology National Clinical Cases 2021 CONTENTS Society for Endocrinology National Clinical Cases 2021 Oral Communications ................................................. OC1–OC10 Highlighted Cases ................................................. NCC1–NCC71 AUTHOR INDEX Endocrine Abstracts (2021) Vol 74 Society for Endocrinology National Clinical Cases 2021 Oral Communications Endocrine Abstracts (2021) Vol 74 Society for Endocrinology National Clinical Cases 2021 OC1 lupus-anticoagulant. 5 days post-admission, in view of sudden onset lower A rare heterozygous IGFI variant causing postnatal growth failure and backache & worsening infection markers, repeat CT CAP was done which offering novel insights into IGF-I physiology revealed new bilateral adrenal haemorrhages. MRI adrenals revealed B/l adrenal 1 1 2 1 haemorrhages with fat stranding ,no underlying adrenal mass noted. Her 9am Emily Cottrell , Sumana Chatterjee , Vivian Hwa & Helen L. Storr ! 1 cortisol was 25, therefore she was started on IV hydrocortisone for acute Centre for Endocrinology, William Harvey Research Institute, Barts and adrenal insufficiency.
    [Show full text]
  • Stanovení Izoenzymů Laktátdehydrogenázy Elektroforézou V Agarózovém Gelu
    Use of enzymes as diagnostic markers Evaluation of lactate dehydrogenase (LDH) isoenzymes by agarose gel electrophoresis Lactate dehydrogenase LDH • tetramer § M (gene LDHA, ch.11) § H (gene LDHB, ch.12) • LDH1 (HHHH) 31-49% – heart, liver, erythrocytes • LDH2 (HHHM) 38-58% – reticuloendothelial system • LDH3 (HHMM) 5.5-16.5% – lungs • LDH4 (HMMM) 0-0.7% – kidney • LDH5 (MMMM) 0-1.5% – skeletal muscle, liver Lactate dehydrogenase § LDH 1 and LDH 2 – converts lactate into pyruvate in tissues with aerobic metabolism § LDH 4 a LDH 5 – converts pyruvate into lactate in tissues with anaerobic glycolysis Electrophoretic separation of LDH isoenzymes • agarose gel, TBE buffer • staining solution – lithium lactate – NAD+ – stain nitroblue tetrazolium – phenazine methosulphate – carrier of electrons between NADH and the dye • 5 % acetic acid Isoenzymes detection • lactate + NAD+ ĺ pyruvate + NADH + H+ • NADH + H+ + NBT ĺ NAD+ + formazan Enzymes • proteins catalyzing chemical reactions (not consumed) • holoenzyme = apoenzyme + cofactor • many enzymes rely on cofactor - small molecules required for the catalytic activity of enzymes - coenzyme - small organic molecules - prosthetic group - tightly bound cofactor • enzymes decrease the required activation energy • thus, in the presence of enzymes, reactions proceed at a faster rate • many enzyme-catalyzed reactions are reversible Enzyme-catalyzed reaction Active site of the enzyme • active site = small portion of enzyme molecule which actually binds the substrate • active site is the result of precise folding of the polypeptide chain - AA that may have been far apart in the linear sequence can come together to cooperate in the enzyme reaction Enzyme specifity • each enzyme has a unique 3-D shape and recognizes and binds only the specific substrate of a reaction • often – reaction with only one substrate • sometimes – reaction with group of similar substrates • eg.
    [Show full text]